Untitled Flashcards Set
1. pdf 1 Overview of Acquired Coagulation Disorders:
- These are bleeding disorders that happen due to other health issues, not from birth.
- Key Causes:
- Vitamin K-Dependent Factor Deficiencies: Involves factors II, VII, IX, X, and proteins S and C, which are essential for clotting.
- Disseminated Intravascular Coagulation (DIC): A serious condition where abnormal clotting and bleeding occur simultaneously.
- Excess Fibrinolysis: Overactivity of the clot-dissolving process, leading to excessive breakdown of clots.
- Liver Disease: The liver produces clotting factors, so liver issues can disrupt normal clotting.
2. Normal Fibrinolysis Process:
- Fibrinolysis is the body’s way of breaking down clots once healing has started.
- Key Components:
- Plasmin: The enzyme that dissolves fibrin, the main component of a clot.
- Plasminogen: The inactive form of plasmin, activated when needed by tissue plasminogen activator (tPA) from healthy cells.
- The breakdown products of fibrin and fibrinogen are called fibrin/fibrinogen degradation products (FDPs).
3. Excess Fibrinolysis (Hyperfibrinolysis):
- Primary Fibrinolysis: Caused by an inherent issue with fibrinolysis, leading to excessive clot breakdown without a trigger like DIC.
- Secondary Fibrinolysis: Triggered by conditions such as DIC, where excess clotting activates fibrinolysis in an attempt to restore balance.
- In secondary fibrinolysis, hyperplasminemia (high plasmin levels) occurs, increasing the breakdown of clots.
4. Causes of Primary Fibrinolysis:
- Various conditions can lead to primary fibrinolysis:
- Heat Stroke
- Hypoxia (lack of oxygen)
- Major Surgery
- Drug Overdose (e.g., barbiturates)
- Severe Liver Disease
5. Pathophysiology (How it Happens) in Primary Fibrinolysis:
- Excessive plasmin activity dissolves clots too quickly, causing:
- Low Fibrinogen (needed for clot formation)
- Low Clotting Factors FV and FVIII
- These changes lead to an increased risk of bleeding.
6. Laboratory Investigation:
- Distinguishing between DIC and primary fibrinolysis is crucial.
- Common Screening Tests:
- CBC (Complete Blood Count): Platelet count can be normal in primary fibrinolysis but is typically low in DIC.
- Blood Film: In DIC, blood cells often appear fragmented due to clotting stress.
- PT (Prothrombin Time), APTT (Activated Partial Thromboplastin Time), TT (Thrombin Time): These times may be prolonged in primary fibrinolysis but are even more prolonged in DIC.
- Fibrinogen Assay: Measures fibrinogen levels, usually low in both conditions.
- D-Dimer: Negative in primary fibrinolysis, positive in DIC, which indicates active clot breakdown.
7. Tests of Fibrinolysis:
- FDP Detection: Tests for fibrin/fibrinogen breakdown products.
- D-Dimer Assay: Uses a latex agglutination immunoassay; elevated levels are seen in DIC and some thrombosis cases.
- Euglobulin Clot Lysis Time: Measures how long it takes for a clot to dissolve. Shorter times indicate excess fibrinolysis.
8. D-Dimer Assay Details:
- Purpose: To detect fibrin breakdown products specifically related to excessive clotting.
- Range: Normal levels are below 500 ng/mL; high levels are seen in DIC, deep vein thrombosis (DVT), and pulmonary embolism (PE).
9. Euglobulin Clot Lysis Time Test:
- This test specifically assesses fibrinolytic activity.
- Principle:
- Plasma is treated to isolate euglobulins, which contain key fibrinolytic factors like plasminogen and tPA.
- Thrombin is added to form a clot, and the time taken for it to dissolve indicates fibrinolytic activity.
- Interpretation: Normal is 90-240 minutes; under 90 minutes suggests excess fibrinolysis and a bleeding risk.
10. Fibrinolytic Drugs:
- Used to temporarily enhance fibrinolysis in emergencies.
- Commonly used drugs include tPA and streptokinase for:
- Heart Attacks: To dissolve artery-blocking clots.
- Strokes: To restore blood flow in the brain.
- Pulmonary Embolism: To break up lung clots.
Here's a comprehensive breakdown for PDF 2 and PDF 3, following the same detailed format as before.
---
### PDF 2: Inherited and Acquired Hypercoagulable States
#### 1. Inherited Hypercoagulable States (Thrombophilia):
- These are genetic conditions where the blood is more prone to clotting, increasing the risk of conditions like deep vein thrombosis (DVT) or pulmonary embolism (PE).
- Key Components:
- Antithrombin (AT): Inhibits key clotting factors like IIa (thrombin), Xa, and others. Low levels can increase clotting risk.
- Protein C: Regulates clotting by inhibiting factors VIIIa and Va and requires Protein S for activation.
- Protein S: A cofactor for Protein C activation.
- Plasminogen: Inactive form of plasmin, which breaks down clots and is activated by tPA (tissue plasminogen activator).
#### 2. Genetic Variants Leading to Hypercoagulability:
- Factor V Leiden:
- Mutation in the factor V gene, making it resistant to inactivation by activated protein C (APC).
- Increases the risk of venous thrombosis; 10% of carriers may develop clots.
- Prothrombin G20210A:
- Mutation where guanine (G) is replaced by adenine (A) at position 20210 in the prothrombin gene, increasing prothrombin levels and clot risk.
- ABO Blood Group:
- Non-O blood types have a higher risk due to higher levels of von Willebrand Factor (vWF) and factor VIII.
#### 3. Hyperhomocysteinemia:
- High homocysteine levels increase risk of blood vessel injury and thrombosis.
- Can be genetic (e.g., enzyme deficiencies like methionine β-synthase deficiency) or acquired (e.g., from low vitamin B6, B12, folate, or other factors like smoking and kidney disease).
#### 4. Acquired Hypercoagulable States:
- Malignancy:
- Cancer (especially ovarian, brain, pancreatic) increases clot risk as tumors release tissue factors that activate factor X.
- Estrogen Therapy:
- Hormone therapy (e.g., birth control, hormone replacement) raises levels of clotting factors, reducing anticoagulant proteins.
- Blood Disorders:
- Conditions like polycythemia vera, essential thrombocythemia, and sickle cell disease increase clot risks due to high blood viscosity and platelet changes.
- Inflammation:
- Chronic inflammation can upregulate clotting and downregulate anticoagulants, raising clot risk.
- Post-Operative Venous Thrombosis:
- Common in elderly and immobile patients after surgery; venous stasis and immobility increase clot formation.
- Antiphospholipid Syndrome:
- An autoimmune disorder with antibodies that affect clotting regulation, increasing risks for both arterial and venous clots.
---
### PDF 3: Thrombosis and Thrombophilia
#### 1. Introduction to Thrombosis:
- Thrombosis is the formation of a solid mass (thrombus) inside blood vessels.
- Balanced Mechanisms:
- Inhibition of Clot Formation: Natural anticoagulants like AT, protein C, and protein S.
- Dissolution of Clots: Fibrinolytic system, which dissolves clots to prevent excessive blockage.
#### 2. Virchow’s Triad:
- Three major factors contributing to thrombosis:
- Stasis: Slowed blood flow, which can lead to clot formation.
- Hypercoagulability: A blood condition making it more prone to clotting.
- Vessel Wall Damage: Injury to blood vessel walls triggers clotting.
#### 3. Types of Thrombosis:
- Deep Venous Thrombosis (DVT):
- Often forms in the lower leg veins. Risks include immobility, age, and surgery.
- Main concern is that DVT can lead to pulmonary embolism (PE).
- Arterial Thrombosis:
- Often triggered by endothelial injury (exposing collagen and tissue factors), leading to blockage of arteries and potentially causing heart attacks or strokes.
#### 4. Inherited Thrombophilia:
- Genetic conditions that increase risk for clot formation:
- Deficiency of Coagulation Inhibitors:
- Antithrombin III (ATIII): Limits thrombin and factor Xa; low levels can lead to increased clot risk.
- Protein C: Needs Protein S for full activity, and inhibits factors FVIIIa and FVa to prevent excess clotting.
- Protein S: Cofactor for Protein C.
- Heparin Cofactor II (HCII): Specifically inhibits thrombin.
- Deficiency of Fibrinolytic Proteins:
- Plasminogen: Activated to plasmin, which breaks down clots.
- Tissue Plasminogen Activator (tPA): Helps activate plasminogen.
#### 5. Clinical Presentation of Thrombophilia:
- Symptoms include recurrent DVT and PE.
- Severe inherited forms may result in fatal thrombosis shortly after birth.
#### 6. Lab Investigation for Thrombophilia:
- Common screening tests include PT, APTT, TT, and platelet count.
- Specific assays measure levels of inhibitors like ATIII, Protein C, and fibrinolytic proteins like plasminogen.
#### 7. Treatment:
- Antithrombotic Drugs: Includes drugs like warfarin (a vitamin K antagonist) and heparin (enhances ATIII activity).
- Replacement Therapy: Providing missing coagulation inhibitors (like ATIII or Protein C) when deficient.
#### 8. Role of Key Anticoagulant Drugs:
- Warfarin: Inhibits vitamin K activity, leading to less active clotting proteins.
- Heparin: Increases activity of ATIII, which inactivates thrombin.
#### 9. Acquired Thrombophilia:
- Develops due to conditions like trauma, disease, or medications that disrupt clotting balance, including:
- Nephrotic Syndrome: Reduces ATIII, protein S, protein C, and fibrinolytic factors.
- Cancer: Tumors may increase tissue factors.
- Surgery and Pregnancy: Increase clotting factors and may reduce natural anticoagulants.
#### 10. Lab Investigation of Acquired Thrombophilia:
- Specific lab markers include increased platelet counts, short PT, APTT, TT times, and elevated FVIII and fibrinogen levels, all indicating an overactive clotting system.
- In DIC, PT, APTT, TT are prolonged with decreased platelets and fibrinogen as DIC progresses.